Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 25.84 USD -3.04% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Beam Therapeutics Inc?
Write Note

EV/OCF
Enterprise Value to OCF

-8.9
Current
-4.2
Median
5.7
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-8.9
=
Enterprise Value
1.2B USD
/
Operating Cash Flow
-135.8m USD
All Countries
Close
Market Cap EV/OCF
US
Beam Therapeutics Inc
NASDAQ:BEAM
2.1B USD -8.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -237 522.5
US
Abbvie Inc
NYSE:ABBV
320.1B USD 22.5
US
Amgen Inc
NASDAQ:AMGN
147.4B USD 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD -132.5
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10.9
US
Epizyme Inc
F:EPE
94.1B EUR -474
AU
CSL Ltd
ASX:CSL
135.4B AUD 35.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 17.8
US
Seagen Inc
F:SGT
39.3B EUR -74.2
NL
argenx SE
XBRU:ARGX
34.3B EUR -126.9
 
US
Beam Therapeutics Inc
NASDAQ:BEAM
Average EV/OCF: 22.6
Negative Multiple: -8.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -237 522.5
US
Abbvie Inc
NYSE:ABBV
22.5
US
Amgen Inc
NASDAQ:AMGN
26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -132.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474
AU
CSL Ltd
ASX:CSL
35.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -74.2
NL
argenx SE
XBRU:ARGX
Negative Multiple: -126.9

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Discover More